Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) – CareAdvantage. This is a data-driven, holistic approach in which JJMD partners with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities.
The healthcare marketplace is changing, with intensifying pressure to meet the ‘triple aim’ of improving outcomes, increasing patient satisfaction and reducing costs. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8119051-johnson-medical-devices-careadvantage/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
LG Chem, la division chimie de LG Group, a signé un partenariat de distribution exclusif pour la France et la Belgique avec Laboderm - filiale de Novomed Group spécialisée en dermatologie et médecine esthétique - pour la distribution de sa gamme YVOIRE, génération innovante de produits de comblement injectables à base d’acide hyaluronique (AH) réticulé d’origine non-animale.
La gamme YVOIRE révolutionne l’offre des produits de comblement. Sa technologie exclusive « HICE » (High Concentration Equalized) se caractérise d’un côté par un haut poids moléculaire pour un effet plus durable et une plus forte élasticité, et de l’autre par une très faible concentration d’agent réticulant BDDE (Butyl Diglycidyl Ether), garantissant plus de sécurité. Au total, sa composition résulte en des produits homogènes, faciles à injecter (fluidité et régularité) et plus résistants à la dégradation enzymatique.
La gamme se décline en trois catégories de produits (« Classic », « Volume », « Contour ») avec ou sans lidocaïne (pour plus de confort), offrant aux praticiens de larges possibilités d’interventions personnalisées selon les patients.
To view the multimedia release go to:
https://www.multivu.com/players/fr/8392651-lg-chem-laboderm-distributeur-yvoire/
After nearly eight years of careful planning, guests from across Illinois gathered today in Lake Forest to celebrate the ceremonial opening of the new Northwestern Medicine Lake Forest Hospital, which will officially open on March 3, 2018.
The new state-of-the-art hospital, which broke ground in 2014, will provide patients convenient access to world-class physicians with seamless access to Northwestern Memorial Hospital, Illinois’s premier academic medical center when needed. The new Lake Forest Hospital will offer cutting-edge treatments and innovative clinical trials within a world class health system.
To view the multimedia release go to:
https://www.multivu.com/players/English/8213351-new-northwestern-medicine-lake-forest-hospital/
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
Kaléo, a privately-held pharmaceutical company, today announced the AUVI-Q® (epinephrine injection, USP) Auto-injector will be available by prescription starting February 14th, and announced AUVI-Q AffordAbility, a first-of-its-kind access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q.
To view the multimedia release go to:
http://www.multivu.com/players/English/7981051-auvi-q-epinephrine-auto-injector-access-and-availability-launch/
NEW YORK, NY (January 28, 2019) – Today, CancerCare celebrated its 75th anniversary by revealing a new campaign “If It Matters To You, It Matters To Us.” The campaign declares CancerCare’s commitment to holistic, patient-centered support services, and celebrates a legacy of comprehensive care for people living with cancer.
“A cancer diagnosis turns a person’s life upside down. Throughout many doctors’ visits, tests and treatments, people with cancer often feel like they’re perceived as a patient rather than a person,” said CancerCare CEO, Patricia Goldsmith. “For 75 years, CancerCare has championed the importance of addressing what matters most to patients and their families through free, direct services to help cope with the emotional, practical and financial challenges of a cancer diagnosis.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8350251-cancercare-75th-anniversary-cancer-community/
Cancer Treatment Centers of America® (CTCA), a national network of comprehensive cancer care hospitals and outpatient care centers, and Foundation Medicine, a leading molecular insights company that recently received FDA approval for its FoundationOne CDx™ genomic test, today announced the launch of a collaborative educational campaign designed to heighten awareness of the promise of precision medicine and the role that advanced genomic testing plays in helping identify treatments best suited for individual patients.
To view the multimedia release go to:
https://www.multivu.com/players/English/8295651-cancer-treatment-centers-of-america-foundation-medicine-precision-cancer-treatment/
The millions of women who experience bladder leakage now have a new option to strengthen and tone away their problem instead of covering it up with pads.
The PeriCoach System is a discreet device and smartphone app that helps women perform at-home pelvic floor muscle training, exercises recommended by the American College of Physicians as first-line treatment for urinary incontinence. PeriCoach is the only system that includes a web portal allowing clinicians to remotely monitor their patients’ progress.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7543451-pericoach-fda-approval/
The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors’ Association, Inc., and Eisai Inc. today announced the launch of Myths and Truths About Thyroid Cancer, an interactive, educational campaign designed to help dispel the myth that thyroid cancer is a “good cancer.” Because most thyroid cancers can be successfully treated, many are told if you are going to get cancer, thyroid cancer is the one to have, which has led to this misperception. However, whether successfully treated or not, the truth is all cancers can have a significant impact on a person’s life, beginning with the shock and distress of hearing the word “cancer” at diagnosis. In honor of Thyroid Cancer Awareness Month and the tens of thousands who receive a thyroid cancer diagnosis each year, Myths and Truths About Thyroid Cancer illustrates the life-changing realities of this disease.
“As a thyroid cancer survivor, I urge people to stop referring to thyroid cancer as the ‘good cancer,’ as I believe it downplays patients’ experiences,” said Joan Shey, founder of the Light of Life Foundation. “I hear time and time again from patients how difficult their diagnosis and treatment were and that their scars are more than skin deep. My hope is that this campaign can educate about the many types of thyroid cancer and change the thyroid cancer conversation.”
“Being part of a community of survivors is very important for people coping with thyroid cancer,” said Gary Bloom, thyroid cancer survivor and co-founder and executive director of ThyCa: Thyroid Cancer Survivors’ Association. “ThyCa takes this to heart, which is why we are proud to provide support and resources to the thyroid cancer community. We also know more needs to be done to elevate awareness of thyroid cancer and what patients need in terms of support for the rest of our lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7595951-eisai-thyroid-cancer-myths/
Motherhood is a lifelong promise to love, protect and fight for your child. For some mothers, the greatest fight isn’t their own – it’s helping their child battle cancer.
Beginning today and throughout May, Northwestern Mutual, through its Foundation, is honoring heroic moms of childhood cancer patients by sharing their inspiring stories of strength. Additionally, the foundation is making a $50,000 grant in support of these moms to Alex’s Lemonade Stand Foundation (ALSF) to help find a cure.
Northwestern Mutual will share the personal stories of eight mothers and their children from across the country through a Facebook campaign.
To view the multimedia release go to:
http://www.multivu.com/players/English/7730651-northwestern-mutual-mothers-day/
Many people think being on hospice means lying in a bed, barely conscious. However, this perception is not an accurate one. Many hospice patients' final moments are spent enjoying quality time with family and friends and creating special moments and memories. This would not be possible without the help of hospice.
The mission of hospice is to provide specialized care for patients in the final weeks and months of life and their families. More simply, hospice care supports living one’s life to the fullest with dignity regardless of how much time remains.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
